You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
AstraZeneca
Medtronic
Mallinckrodt
Merck

Last Updated: March 31, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR RUBRACA

» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for RUBRACA

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02986100 Absorption, Metabolism, and Excretion Following a Single Oral Dose of [14C]-Rucaparib Active, not recruiting Clovis Oncology, Inc. Phase 1 2016-11-01 The purpose of this study is to characterize the mass balance, absorption, metabolism, and elimination pathways of orally administered [14C] rucaparib followed by cycle by cycle treatment with rucaparib continuing until disease progression or other reason for discontinuation
NCT03318445 Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair Not yet recruiting Clovis Oncology, Inc. Phase 1 2017-11-01 This is an open label, non-randomized, dose escalation and expansion Phase Ib trial to evaluate the safety and recommended phase II dose of the combination of irinotecan and rucaparib.
NCT03318445 Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair Not yet recruiting Pamela Munster Phase 1 2017-11-01 This is an open label, non-randomized, dose escalation and expansion Phase Ib trial to evaluate the safety and recommended phase II dose of the combination of irinotecan and rucaparib.
NCT03442556 Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency Not yet recruiting National Cancer Institute (NCI) Phase 2 2018-05-15 This phase II trial studies how well docetaxel, carboplatin, and rucaparib camsylate work in treating patients with castration resistant prostate cancer with homologous recombination deoxyribonucleic acid (DNA) repair deficiency that has spread to other places in the body. Drugs used in chemotherapy, such as docetaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Rucaparib camsylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving induction docetaxel and carboplatin followed by maintenance rucaparib camsylate may work better in treating patients with castration resistant prostate cancer.
NCT03442556 Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency Not yet recruiting University of Washington Phase 2 2018-05-15 This phase II trial studies how well docetaxel, carboplatin, and rucaparib camsylate work in treating patients with castration resistant prostate cancer with homologous recombination deoxyribonucleic acid (DNA) repair deficiency that has spread to other places in the body. Drugs used in chemotherapy, such as docetaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Rucaparib camsylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving induction docetaxel and carboplatin followed by maintenance rucaparib camsylate may work better in treating patients with castration resistant prostate cancer.
NCT03521037 Rucaparib Hepatic Impairment Study in Patients With a Solid Tumor Recruiting Clovis Oncology, Inc. Phase 1 2018-03-31 Phase 1, open-label, parallel group, PK, safety and tolerability study in patients with an advanced solid tumor and either normal hepatic function (Group 1, n = 8) or moderate hepatic impairment (Group 2, n = 8) according to the NCI-ODWG criteria. Patients in Group 1 and Group 2 may be enrolled in parallel, with preferential enrollment of Group 2 patients before Group 1 patients. The study will consist of 2 parts: a single-dose PK part (Part I) and a continuous rucaparib treatment part (Part II).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for RUBRACA

Condition Name

Condition Name for RUBRACA
Intervention Trials
Solid Tumor 3
BRCA2 Gene Mutation 2
Epithelial Ovarian Cancer 2
Urothelial Carcinoma 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for RUBRACA
Intervention Trials
Prostatic Neoplasms 4
Carcinoma 3
Ovarian Neoplasms 3
Adenocarcinoma 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for RUBRACA

Trials by Country

Trials by Country for RUBRACA
Location Trials
United States 24
Slovakia 2
Hungary 2
Poland 2
Australia 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for RUBRACA
Location Trials
Texas 2
Ohio 2
Massachusetts 1
Tennessee 1
Rhode Island 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for RUBRACA

Clinical Trial Phase

Clinical Trial Phase for RUBRACA
Clinical Trial Phase Trials
Phase 3 1
Phase 2 5
Phase 1/Phase 2 3
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for RUBRACA
Clinical Trial Phase Trials
Not yet recruiting 8
Recruiting 6
Active, not recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for RUBRACA

Sponsor Name

Sponsor Name for RUBRACA
Sponsor Trials
Clovis Oncology, Inc. 13
Bristol-Myers Squibb 3
Foundation Medicine 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for RUBRACA
Sponsor Trials
Industry 21
Other 11
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Express Scripts
McKinsey
Merck
Moodys
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.